Clinical Trial

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Study acronym: DME
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Protocol Amendment History 7 changes
notable Trial sites expanded: 70 -> 73 locations 2026-08-05
notable Trial sites expanded: 65 -> 70 locations 2026-07-07
notable Trial sites expanded: 46 -> 65 locations 2026-06-04
notable Trial sites expanded: 39 -> 46 locations 2026-05-07
notable Trial sites expanded: 3 -> 39 locations 2026-04-08
notable Primary completion pushed: 2027-08 -> 2027-10 2026-04-08
minor Completion pushed: 2028-08 -> 2028-10 2026-04-08
Trial Details
NCT Number NCT07449936
Lead Sponsor EyePoint Pharmaceuticals, Inc.
Conditions Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Enrollment 240 participants
Start Date 2026-02-16
Primary Completion 2027-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-04